Diagnostic Criteria and Definitions
Substance- or medication-induced psychotic disorder is defined by new-onset delusions or hallucinations occurring in close temporal association with drug or medication use. DSM-5-TR requires that (A) prominent delusions or hallucinations are present; (B) these symptoms develop “during, or within a month” of intoxication or withdrawal of a substance (or exposure to a medication); and (C) the disturbance is not better explained by a primary psychotic disorder (e.g. symptoms existed before use or persist long after clearance). ICD-11 similarly emphasizes a causal link: symptoms must arise “during or soon after intoxication or withdrawal” with a substance known to cause psychosis, and be markedly in excess of ordinary intoxication/withdrawal effects. The psychotic disturbance must impair functioning (Criterion E) and not be due to delirium. In practice, diagnostic guidelines stress careful timelines and collateral history: for example, some youths with emerging schizophrenia use drugs early, so prior mental status must be checked. In ICD-11, the “substance-induced” specifier is valid only if timing and severity clearly exceed expected drug effects; causality is inferred but not proven.
Temporal Onset: Intoxication, Withdrawal, or Medication Exposure
Key to diagnosis is timing. Onset of psychosis should coincide with substance effects – during acute intoxication or withdrawal (often within hours to days) – and worsen with greater exposure. Most stimulant-induced psychoses emerge while the patient is acutely under the drug’s influence (for example, during a binge) and often abate after the drug wears off. DSM-5-TR explicitly notes symptoms must occur “during, or within a month” of use (Criterion B). In contrast, a psychosis arising long after use ceased, or one that began prior to drug use, favors a primary psychotic disorder. For example, amphetamine or cocaine psychoses often appear within days of heavy use and may last days to weeks, but if delusions persist months after abstinence, schizophrenia must be reconsidered. Conversely, withdrawal states (e.g. delirium tremens from alcohol, or benzodiazepine withdrawal) can also precipitate hallucinations and paranoia, which classically arise 2–7 days after cessation. Clinicians use the substance’s pharmacokinetics to interpret timing: for instance, methamphetamine has a half-life around 10–20 hours, so a positive urine level indicates use in the past 1–3 days. Similarly, LSD psychosis usually follows use by minutes to hours. Careful timeline reconstruction (including last use and symptom onset) is therefore essential in assessing causation.
Psychoactive Substances Linked to Psychosis
Many recreational and illegal drugs are well-known psychotomimetics. Stimulants (amphetamine-type drugs, cocaine, methamphetamine) can trigger frank psychosis, especially with heavy or chronic use. Cocaine intoxication commonly causes paranoid delusions and auditory/visual hallucinations. Amphetamines (including MDMA/ecstasy and “bath salts”) similarly produce hypervigilance, agitation, and persecutory misperceptions; their induced psychoses often involve tactile hallucinations (“bugs crawling”) and bizarre delusions. Cannabis and synthetic cannabinoids (e.g. “spice”) can also precipitate transient psychosis, especially in high-potency use; cannabis psychosis often mimics schizophrenia with paranoia and auditory hallucinations. Hallucinogens (LSD, psilocybin) induce mostly visual and sensory distortions, but in some cases can provoke prolonged paranoia or “bad trip” delusions during and immediately after intoxication. Phencyclidine (PCP) and ketamine cause marked dissociation and agitation, with combativeness and persecutory delusions. Other substances in overdose or withdrawal that can mimic psychosis include alcohol (particularly in delirium tremens), anticholinergics (causing delirious hallucinations), and inhalants (resulting in confusion and hallucinations). In summary, amphetamines, cocaine, cannabis, hallucinogens, inhalants, and some sedative/hypnotics are commonly associated with psychotic symptoms.
Medication-Induced Psychosis
A wide range of prescribed drugs and medical treatments can precipitate psychosis in susceptible individuals. High-dose corticosteroids (e.g. prednisone 40–80 mg/day or equivalent) are notorious triggers: systematic reviews report new psychiatric symptoms in a substantial fraction of patients on systemic steroids, including formal psychotic syndromes in up to ~4–20%. Anticholinergic drugs (e.g. benztropine, high-dose scopolamine) and antihistamines can cause delirium with hallucinations. Dopaminergic agents (L-DOPA and ergot agonists for Parkinson’s disease) often produce visual hallucinations and paranoia. Some antibiotics (notably fluoroquinolones, isoniazid, TMP-SMX) and antimalarials (e.g. mefloquine) can produce psychotic reactions. Other culprits include immunosuppressants (cyclosporine), interferons, prescription stimulants for ADHD, anticonvulsants, antidepressants (especially MAO inhibitors or bupropion in high doses), and illicit dopamine agonists (like synthetic cathinones). In short, iatrogenic causes range from corticosteroids to antiparkinson drugs and antimicrobials; when evaluating psychosis, a detailed medication history is as important as the illicit drug history.
Stimulant-Related Symptoms: Hypervigilance, Insomnia, Hallucinations
Stimulant intoxication often causes a distinct cluster of symptoms. Patients are hyperalert, restless and anxious, frequently reporting that they feel watched or followed. They may engage in repetitive checking behaviors (locking doors, scanning the room) out of paranoia. Severe stimulants can trigger tactile hallucinations such as formication (“bugs crawling on skin”), which provoke intense scratching or picking. Auditory and visual hallucinations often revolve around persecution or threat (e.g. hearing voices of spies or seeing hidden bugs), and delusions are typically paranoid (e.g. police/espionage theories). Sleep is markedly disrupted: insomnia is nearly universal, which further feeds paranoia. The stimulant-induced psychosis can resemble acute paranoid schizophrenia but often lacks the negative symptoms (flat affect, social withdrawal) of a primary psychotic disorder. Clinical summaries note that hallucinations, paranoia, and acute agitation are hallmarks of stimulant psychosis. Importantly, most stimulant psychoses resolve quickly: case reports and clinical series show that symptoms usually subside within days to a week of stopping the drug. Persistence beyond one week of abstinence should prompt re-evaluation of the diagnosis.
Interpreting Toxicology: Causation vs. Coincidence
A positive toxicology screen alone does not prove causation of psychosis. Many individuals with primary schizophrenia or bipolar disorder also use substances, and a drug may be an epiphenomenon rather than the cause of delusions. Clinicians must be wary of overattributing psychosis to drugs without corroborating evidence. DSM-5 itself cautions that a substance-induced diagnosis should not be made if an independent psychotic disorder better explains the picture. For example, if psychotic symptoms began before heavy drug use, or if symptoms persist substantially longer than the drug’s known effects, a primary psychotic illness is likely. Similarly, focal findings (like focal neurological signs) or a strong family history of schizophrenia argue against a purely substance cause. In practice, one must distinguish factual encounters from delusional interpretations: a patient’s belief that “the CIA put bugs in my wall” remains a delusion even if a police car actually drove by recently. Clinicians should not confirm or dramatize unverified claims of surveillance. Instead, emphasize evidence-based facts (e.g. reassure that no hidden cameras were found) while validating the patient’s distress. Thus, a toxicology report is one piece of data; careful history, collateral information, and clinical judgment are needed to infer causality.
Differentiating Substance-Induced vs. Primary Psychosis
Differentiation rests on course and context. Substance-induced psychosis by definition has a close temporal link to use and often resolves with abstinence. Primary psychotic disorders (schizophrenia, schizoaffective) typically have a more insidious onset, longer duration (>6 months), and often include negative or cognitive symptoms. Empirically, those with pure substance-induced psychoses tend to have fewer negative symptoms and better insight than schizophrenia patients. They more commonly report visual or tactile hallucinations, whereas primary schizophrenia more often involves entrenched auditory hallucinations and flat affect. A family history of psychosis or early poor social function suggests a primary disorder. Formal criteria (DSM-5-TR, ICD-11) use the rule-out approach: if delusions existed prior to substance use, or persist beyond the typical clearance (more than ~1 month later), then a diagnosis like schizophrenia or schizoaffective disorder is favored. Longitudinally, about 20–25% of cases initially diagnosed as substance-induced later receive a schizophrenia diagnosis. Rates vary by drug type: transitions are high after cannabis (≈34–46%) or hallucinogen psychoses, and much lower after alcohol or opioid-related psychoses. Clinicians should thus maintain diagnostic uncertainty initially; re-assessment after a period of abstinence (e.g. 4–6 weeks) is essential before confirming a primary psychotic disorder.
Persistent Symptoms and Follow-Up
If psychotic symptoms persist after sustained abstinence, this raises concern for an underlying primary disorder. DSM-5 notes that persisting symptoms beyond “a substantial period (about 1 month)” after intoxication is inconsistent with a substance-induced diagnosis. For example, methamphetamine psychosis usually clears within days, so hallucinations lasting weeks to months warrant re-evaluation. Such patients should receive close follow-up (often in an early psychosis program). Empirical studies confirm this approach: specialized programs report that about a quarter of initial substance-induced cases are reclassified as schizophrenia within a year. Clinicians should warn patients and families that long-term monitoring is needed. During follow-up, emphasis is on reassessing diagnosis and differentiating residual drug effects (e.g. neurotoxicity) from true psychosis. Ongoing abstinence, symptom tracking, and periodic mental status exams help determine whether antipsychotic medication can be tapered or must be maintained.
Acute Medical Management
Initial stabilization is paramount. In the ED or crisis setting, ABCs (airway, breathing, circulation) take precedence. Vital signs should be monitored closely, with particular attention to hydration, hyperthermia (common in stimulant overdose), and rhabdomyolysis. Patients with agitated psychosis from stimulants often require rapid sedation. Benzodiazepines (lorazepam, midazolam) are first-line for stimulant or alcohol-related agitation: they safely calm the patient and reduce sympathomimetic drive. Haloperidol or atypical antipsychotics are also used for severe agitation and to treat psychotic symptoms, but clinicians weigh risks (e.g. lowering seizure threshold, QT prolongation). Evidence does not show clear superiority of one over the other; current reviews suggest tailoring treatment to the situation. As soon as safely possible, the substance should be discontinued or detox protocols initiated (e.g. benzodiazepines for alcohol or sedative withdrawal). Creating a quiet, low-stimulation environment with reassurance is also therapeutic. In many cases, short-term antipsychotics (e.g. a few days of risperidone or haloperidol) help psychosis abate if extremely severe, especially with dopaminergic drugs. For LSD or non-dopaminergic hallucinogens, however, “therapeutic observation” alone is often sufficient. Throughout, avoid direct confrontation about delusional beliefs; instead, provide factual corrections tactfully (e.g. “I see no evidence of cameras here”).
Ongoing Care: Addiction Treatment and Support
Once acute symptoms are controlled, focus shifts to substance-use treatment and psychosocial support. Integrated dual-diagnosis programs (combining mental health and addiction services) yield better outcomes than separate treatments. Patients benefit from relapse-prevention counseling (cognitive-behavioral therapy, motivational interviewing) and medications if indicated (e.g. naltrexone for alcohol, buprenorphine for opioids). Ensuring stable housing and a supportive environment is critical: evidence-based care includes family therapy, supported employment/education, and case management. Providers should offer harm-reduction resources as needed (e.g. needle exchange, naloxone for overdose), while strongly encouraging abstinence from the psychosis-triggering substances. Social support – involving family or community agencies – can reduce isolation and prevent homelessness, which in turn lowers relapse risk. In all communications, language should be nonjudgmental to avoid stigma (do not call patients “addicts” or criminals). Encourage linkage to peer-support or outpatient psychosocial programs. The goal is a long-term plan that addresses both the psychosis and its root in substance use, recognizing that addiction is a chronic relapsing disorder requiring ongoing attention.
Case Vignette (Illustration)
Patient: A 29-year-old man with a history of heavy methamphetamine use presents to the ED for evaluation of paranoia. Timeline: He reports a 10-day binge of methamphetamine, sleeping only sporadically. On day 7 of the binge, he began “hearing voices from the police radio” and believing federal agents had bugged his apartment. The voices escalated and he became unable to sleep or eat. On the night of presentation (day 10), he was brought in by friends. Exam: He is hypervigilant and agitated, insisting detectives are in the hospital hallway. He has tactile hallucinations (“ants crawling under my skin”) and insists he must avoid the “government drones” monitoring him. He has no disorganized speech, but is severely mistrustful. Vitals show mild hypertension and tachycardia; otherwise normal. Toxicology: Urine screen is positive for methamphetamine and THC. (Urine amphetamines typically indicate use in the past 2–3 days.) A blood panel shows no metabolic derangements. Collateral: Friends say he has no prior psychiatric history, but did have occasional paranoid thoughts after heavy meth use in the past. Family notes no history of mental illness or violence. He has no real interactions with law enforcement except one traffic stop a year ago (no arrest). Diagnostic Impression: His timeline is highly suggestive of substance-induced psychosis: prominent psychotic symptoms began mid-binge and are occurring in the context of confirmed stimulant intoxication. There is no evidence these delusions predated substance use or are proportionately worse than typical intoxication. Thus, a provisional diagnosis of Stimulant-Induced Psychotic Disorder is made. However, because of the intensity and duration, we plan to re-evaluate after a drug-free interval (DSM-5-TR requires that persisting symptoms >1 month may imply a primary disorder). Family is counseled that cessation of methamphetamine is urgent, and that if symptoms do not resolve with abstinence, schizophrenia cannot be ruled out yet. Management Plan: Acute management includes a calm room, IM lorazepam for agitation, and low-dose haloperidol to target the psychosis (addressing the dopaminergic mechanism). We ensure hydration and cooling (patients on stimulants often overheat). On day 2, his persecutory delusions begin to lessen and he sleeps. He will be closely followed: if in 2–4 weeks he remains psychotic off substances, we will consider restarting antipsychotic treatment. Meanwhile, he is referred to an addiction counselor for intensive outpatient rehabilitation and connected with housing and support services. This case illustrates the need to weigh both substance effects and potential primary illness, using timeline and collateral information to guide diagnosis, and to never validate delusional surveillance claims without proof.
Sources: Authoritative psychiatric and toxicology references (DSM-5-TR, ICD-11 guidelines, emergency and addiction medicine literature) were used to summarize definitions, substance associations, clinical features, and management. These sources emphasize evidence-based, non-stigmatizing care and illustrate that toxicology positivity alone does not confirm causation. All claims have been independently verified from peer-reviewed psychiatric and medical texts.
